Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Edward Paule who wrote (9794)	5/5/1999 1:25:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Mention was made in press release prior to the report. XOMA explained the nature of each firm. Prior to hiring these firms it is possible that XOMA would have done a deal if offered one they felt was acceptable and also possible they may have at times made sporadic contacts with logical potential partners. Contracting out the process, IMO, does mean they are more serious and having a third party involved makes the process more efficient. I could go into why I think it is more efficient. The now does relate to the ending of the meningo trial, cash needs, a desire to get moving with Mycoprex, and Iprex, which is not possible without partners, more than just actual cash needs. Nov. 13 98 PR. XOMA scientists recently presented the first data demonstrating oral availability of its Mycoprex fungicidal compounds at ICAAC; the Company has engaged Vector Securities International, Inc. as advisor for pursuing a strategic relationship with a pharmaceutical company partner for Mycoprex. Similarly, LM&E Company Advisors (an ophthalmic consulting company) is assisting XOMA in licensing efforts for the I-PREX topical ophthalmic product.